Discounted Cash Flow
Oncology Institute, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2020 | $187.5m | $-441.2k | $-1.8m | -0.2% | $-0.24 |
| 2021 | $203.0m (8.3%) | $-10.6m (-2309.1%) | $-35.5m (-1899.8%) | -5.2% (-2125.3%) | $-0.16 (33.3%) |
| 2022 | $252.5m (24.4%) | $68.0k (100.6%) | $-67.3m (-89.4%) | 0.0% (100.5%) | $0.00 (100.0%) |
| 2023 | $324.2m (28.4%) | $-67.9m (-99919.1%) | $-40.9m (39.2%) | -20.9% (-77828.6%) | $-0.92 |
| 2024 | $393.4m (21.3%) | $-53.0m (21.9%) | $-30.3m (25.8%) | -13.5% (35.6%) | $-0.71 (22.8%) |
| 2025 | $502.7m (27.8%) | $-50.3m (5.1%) | $-27.8m (8.4%) | -10.0% (25.7%) | $-0.54 (23.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.